About ESSA Pharma (NASDAQ:EPIX)
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPIX
CUSIPN/A
Phone778-331-0962
Debt
Debt-to-Equity Ratio-0.84%
Current Ratio0.62%
Quick Ratio0.62%
Price-To-Earnings
Trailing P/E Ratio-9.40
Forward P/E Ratio-19.79
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.15) per share
Price / Book-25.07
Profitability
EPS (Most Recent Fiscal Year)($0.40)
Net Income$-4,720,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-216.78%
Miscellaneous
Employees15
Outstanding Shares115,520,000
ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions
What is ESSA Pharma's stock symbol?
ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."
How were ESSA Pharma's earnings last quarter?
When is ESSA Pharma's next earnings date?
What price target have analysts set for EPIX?
3 Wall Street analysts have issued 1 year price targets for ESSA Pharma's shares. Their forecasts range from $0.70 to $0.70. On average, they anticipate ESSA Pharma's share price to reach $0.70 in the next twelve months. View Analyst Ratings for ESSA Pharma.
Who are some of ESSA Pharma's key competitors?
Some companies that are related to ESSA Pharma include GT Biopharma (GTBP), Novan (NOVN), Aileron Therapeutics (ALRN), Cardiome Pharma (CRME), Medicure (MCUJF), Pharmaxis (PXSLY), OncoSec Medical (ONCS), Novelion Therapeutics (NVLN), MEI Pharma (MEIP), Alimera Sciences (ALIM), Oncolytics Biotech (ONCYF), Elite Pharmaceuticals (ELTP), Northwest Biotherapeutics (NWBO), Oasmia Pharmaceutical (OASM) and SteadyMed (STDY).
Who are ESSA Pharma's key executives?
ESSA Pharma's management team includes the folowing people:
- Dr. David Ross Parkinson, Pres, CEO & Director (Age 68)
- Mr. David S. Wood, CFO & Principal Accounting Officer (Age 61)
- Mr. Peter A. Virsik, Exec. VP & COO (Age 47)
- Dr. Raymond Andersen, CTO, Sec. & Director (Age 71)
- Dr. Marianne D. Sadar, Chief Scientific Officer & Director (Age 57)
Has ESSA Pharma been receiving favorable news coverage?
Media stories about EPIX stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ESSA Pharma earned a news impact score of 0.13 on Accern's scale. They also assigned news articles about the company an impact score of 47.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of ESSA Pharma?
Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ESSA Pharma's stock price today?
One share of EPIX stock can currently be purchased for approximately $3.76.
How big of a company is ESSA Pharma?
ESSA Pharma has a market capitalization of $19.99 million. The company earns $-4,720,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. ESSA Pharma employs 15 workers across the globe.
How can I contact ESSA Pharma?
ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962.
MarketBeat Community Rating for ESSA Pharma (EPIX)
MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe EPIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
ESSA Pharma (NASDAQ:EPIX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for ESSA Pharma in the last 12 months. Their average twelve-month price target is $0.70, suggesting that the stock has a possible downside of 81.38%. The high price target for EPIX is $0.70 and the low price target for EPIX is $0.70. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $0.70 | $0.70 | $9.00 | $9.00 |
| Price Target Upside: | 81.38% downside | 250.00% upside | 3,813.04% upside | 2,854.69% upside |
ESSA Pharma (NASDAQ:EPIX) Consensus Price Target History
ESSA Pharma (NASDAQ:EPIX) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
ESSA Pharma (NASDAQ:EPIX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ESSA Pharma (NASDAQ EPIX) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 5.97%
ESSA Pharma (NASDAQ EPIX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
ESSA Pharma (NASDAQ EPIX) News Headlines
| Source: |
|
ESSA Pharma (NASDAQ:EPIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ESSA Pharma (NASDAQ:EPIX) Income Statement, Balance Sheet and Cash Flow Statement
ESSA Pharma (NASDAQ EPIX) Stock Chart for Thursday, April, 26, 2018
Loading chart…
